BioCentury | Jun 20, 2019
Translation in Brief

Turning Tregs against cancer

...immunotherapies. To reprogram the cells, the team went after Treg signaling pathways, in particular the CARD11-BCL10-MALT1...
...authors declined to disclose the patent and licensing status of their research. Targets: BCL10 - B cell CLL lymphoma 10...
...Programmed cell death 1 ligand 1; TNF - Tumor necrosis factor Hongjiang Li, Staff Writer Massachusetts General Hospital B cell CLL lymphoma 10 (BCL10) Caspase...
BioCentury | Jun 11, 2019
Distillery Therapeutics

Inhibiting BCL10 or MALT1 for melanoma

...DISEASE CATEGORY: Cancer INDICATION: Melanoma Mouse studies suggest inhibiting BCL10 or MALT1 could help treat melanoma...
...syngeneic mouse model of melanoma, Treg-specific knockout of BCL10 decreased tumor size compared with normal BCL10...
...Next steps could include identifying and testing BCL10 inhibitors in animal models of melanoma. TARGET/MARKER/PATHWAY: B cell CLL lymphoma 10 (BCL10)...
BioCentury | May 16, 2017
Distillery Techniques

Biomarkers

...TNFAIP3 ; A20), PR domain containing 1 with ZNF domain ( PRDM1 ; BLIMP1), B cell CLL lymphoma 10 (BCL10)...
...Marine, Flanders Institute for Biotechnology (VIB), Leuven, Belgium email: jeanchristophe.marine@kuleuven.vib.be Hongjiang Li Aix-Marseille University Flanders Institute for Biotechnology (VIB) B cell CLL lymphoma 10 (BCL10) NK3...
BioCentury | Sep 5, 2013
Distillery Techniques

Technology: Drug platforms

...cells, small molecule inhibitors of survivin (BIRC5), such as sepantronium, and small molecule inhibitors of B cell CLL lymphoma 10 (BCL10)...
...the untreated cell mixtures did. Next steps include developing more specific inhibitors of survivin and BCL10...
Items per page:
1 - 4 of 4